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background:  We evaluated the in-hospital mortality, total costs for hospitalization, and length of stay associated with transcatheter aortic valve 
replacement (TAVR) compared with surgical aortic valve replacement (SAVR) in 2012 using the National Inpatient Sample database (NIS).<
methods:  In-hospital all-cause mortality, mean total costs for hospitalization and median length of stay were compared for TAVR versus SAVR 
from the 2012 version of NIS. A matched propensity score-adjusted model including demographic and patient characteristics including all 17 
components of the Charlson comorbidity index, was constructed to assess the outcomes with TAVR in comparison with SAVR.
results:  Among 16,632 patients with aortic stenosis treated with TAVR (N=1528) or SAVR(N=15,104), 669(4%) patients died during 
hospitalization. TAVR was reserved for patients with higher co-morbidities. In-hospital all-cause mortality with TAVR was 4.78% vs 3.94% 
for SAVR (OR 1.22, 95% CI 0.95-1.57, P=0.12). Mean total hospitalization charge was comparable for TAVR and SAVR (in the propensity 
score-adjusted analysis ($223,999 for TAVR vs $226,110 for SAVR, P=0.24).Median length of stay was shorter with TAVR in the unadjusted 
(8 days vs 11 days), as well as the adjusted models.(Table 1).
Conclusion:  In the very first year after regulatory approval in the US, TAVR had comparable in-hospital mortality and hospitalization costs 
to SAVR, and a significantly lower median duration of hospitalization.
Table 1.
Unadjusted (N=16,632) Propensity Score Adjusted (N=2976)
TAVR(N=1528) Surgical AVR(N=15,104) P-value TAVR(N=1438) Surgical AVR(N=1438) P-value
Baseline Characteristics
Mean Age (SD) 81(9) 67(15) <0.001 80 80 0.19
Women(%) 49 36 <0.001 48.76 47.05 0.37
Caucasian(%) 79 76 0.008 84.13 85.61 0.27
African-American(%) 3.4 5.4 0.0006 3.6 4.6 0.18
Others(%) 17.6 18.6 0.26 12.27 9.79 0.13
AMI(%) 12.37 10.96 0.095 11.98 10.49 0.21
CHF(%) 70 34.9 <0.001 69.59 72.64 0.074
PVD(%) 16.2 19.6 0.001 15.45 13.39 0.12
Stroke/TIA(%) 10.99 9.13 0.017 10.91 8.51 0.03
Dementia(%) 0.46 0.09 <0.001 0.35 0.57 0.4
COPD(%) 30.63 18.18 <0.001 30.19 28.63 0.36
Rheumatoid Disease(%) 4.19 2.41 <0.001 4.1 4.3 0.85
Peptic Ulcer Disease(%) 1.24 0.72 0.026 1.3 1.7 0.36
Mild Liver Disease(%) 1.24 0.36 <0.001 1.1 1.3 0.49
Diabetes(%) 26.77 22.95 0.001 26.44 23.74 0.1
Diabetes with Complications(%) 2.81 2.95 0.76 2.6 2.5 0.81
Hemiplegia/Paraplegia(%) 1.37 1.2 0.56 1.4 1.1 0.39
Renal Disease(%) 32.98 14.28 <0.001 32.96 35.58 0.14
Cancer(%) 3.34 2.09 0.002 3.47 4.11 0.38
Severe Liver Disease(%) 0.59 0.43 0.37 0.57 0.43 0.59
Metastatic Cancer(%) 0.79 0.21 <0.001 0.8 0.9 0.68
AIDS(%) 0 0.11 0.19 0 0 Not Applicable
Outcomes Unadjusted Propensity Score Adjusted
Death 4.78 3.94 0.12 4.79 3.96 0.44
Total Hospitalization Cost($) 218,856 207,498 0.025 223,999 226,110 0.24
Mean Length of Stay (Days) 8 11 <0.001 8 13 <0.001
